How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology

Chayakrit Krittanawong¹, Kipp W Johnson², Wh Wilson Tang^{3

4

5}

Affiliations

¹ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
² Department of Genetics & Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
³ Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, OH, 44195, USA.
⁴ Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland, OH, 44195, USA.
⁵ Center for Clinical Genomics, Cleveland Clinic, Cleveland, OH, 44195, USA.

Chayakrit Krittanawong et al. Per Med. 2019 Mar.

. 2019 Mar;16(2):83-88.

doi: 10.2217/pme-2018-0130. Epub 2019 Mar 6.

Chayakrit Krittanawong¹, Kipp W Johnson², Wh Wilson Tang^{3

4

5}

¹ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
² Department of Genetics & Genomic Sciences, Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
³ Department of Cardiovascular Medicine, Heart & Vascular Institute, Cleveland Clinic, OH, 44195, USA.
⁴ Department of Cellular & Molecular Medicine, Lerner Research Institute, Cleveland, OH, 44195, USA.
⁵ Center for Clinical Genomics, Cleveland Clinic, Cleveland, OH, 44195, USA.

No abstract available

Keywords: artificial intelligence; clinical trials; deep learning; machine learning; precision cardiovascular medicine; precision medicine.

MeSH terms